BRIEF — Verastem To Open TARGET — D 301 1L mPDAC Trial By Year — End 2026
Oct 14 (Reuters) — Verastem Inc: Versus-7375 Demonstrates Robust Anti-tumor Activity Across Advanced Kras G12d-mutant Cancers, Highlighted By 50% Confirmed Orr In 2l Pancreatic Ductal Adenocarcinoma And Two Complete Responses In 2l+ Disease (One Confirmed) Verastem - To Open Target-d 301 1l Mpdac Trial By Year-end 2026